Loading...
For years the arthritis relief medication Exenol has been available without a prescription. This year Parconin was introduced on the market, but, due to government regulations, the drug is available only by prescription. The makers of Parconin argue that it is unfair to restrict access to Parconin while allowing their competition's product to be sold without restrictions, since the two drugs have the same active ingredient and Parconin's other ingredients are harmless.
The answer to which of the following would be most useful in evaluating the argument of the Parconin executives?
| Text from Passage | Analysis |
|---|---|
| For years the arthritis relief medication Exenol has been available without a prescription. |
|
| This year Parconin was introduced on the market, but, due to government regulations, the drug is available only by prescription. |
|
| The makers of Parconin argue that it is unfair to restrict access to Parconin while allowing their competition's product to be sold without restrictions, since the two drugs have the same active ingredient and Parconin's other ingredients are harmless. |
|
The passage starts by establishing that one arthritis drug (Exenol) has been freely available, then introduces a new competitor (Parconin) that faces prescription restrictions. Finally, it presents Parconin's makers' complaint that this difference in treatment is unfair given the medical similarities between the drugs.
Parconin's makers argue it's unfair that their drug requires a prescription while Exenol doesn't, since both drugs have the same active ingredient and Parconin's other ingredients are harmless.
The argument uses a comparison-based logic: if two drugs are medically equivalent (same active ingredient + harmless other components), then they should receive the same regulatory treatment. The unfairness claim rests on the premise that similar medical products should face similar access restrictions.
Evaluate - We need to find what information would help us judge whether Parconin's makers have a valid argument about the unfair regulatory treatment
The argument makes specific claims about ingredient similarity (same active ingredient) and safety (harmless other ingredients), but doesn't address why regulations might differ despite these similarities
For evaluate questions, we need to think of assumptions underlying the argument and create scenarios that would either strengthen or weaken the conclusion when we get more information. The Parconin makers assume that having the same active ingredient and harmless other ingredients should result in the same regulatory treatment. We need to identify what additional information would help us test this assumption.
This focuses on Exenol's makers' opinions about regulations, but their endorsement or opposition doesn't help us evaluate whether Parconin's makers have a valid complaint about unfair treatment. The regulatory decision should be based on medical and safety factors, not competitor opinions. This information wouldn't help us judge the merits of the argument.
This directly tests a crucial assumption in Parconin's makers' argument. They claim both drugs have the 'same active ingredient' and should therefore receive equal treatment. However, if Parconin contains a significantly higher concentration of the active ingredient per dose, this could justify requiring medical supervision (prescription) while allowing the lower-dose Exenol to be sold over-the-counter. This information would be essential for evaluating whether the regulatory difference is actually unfair or medically justified.
While this might provide some context about the broader market, it doesn't help us evaluate whether the specific regulatory difference between Parconin and Exenol is justified. The argument focuses on comparing these two drugs, and information about other drugs wouldn't directly address whether their different regulatory treatment is fair or unfair.
Cost differences don't address the core issue of whether the regulatory treatment is medically and safety-wise justified. Parconin's makers are arguing about fairness based on ingredient similarity and safety, not economics. Price information wouldn't help us evaluate whether their regulatory complaint has merit from a medical standpoint.
Prescription volume data tells us about market demand but doesn't help evaluate whether requiring prescriptions for Parconin while allowing over-the-counter sales of Exenol is justified. The number of prescriptions doesn't address the underlying medical or safety reasons for the regulatory difference.